{"id":1827,"date":"2026-04-09T13:07:30","date_gmt":"2026-04-09T13:07:30","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:07:30","modified_gmt":"2026-06-26T13:07:30","slug":"kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/","title":{"rendered":"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs"},"content":{"rendered":"\n<p><strong>Montr\u00e9al, Canada \u2013 Strasbourg, France \u2013 Boston, \u00c9tats-Unis, 9 Avril, 2026:&nbsp;<\/strong>Kainova Th\u00e9rapeutiques ( \u00ab la Soci\u00e9t\u00e9 \u00bb ), un acteur cl\u00e9 dans l\u2019innovation th\u00e9rapeutique en immuno-oncologie et en inflammation, a annonc\u00e9 aujourd&#8217;hui le traitement du premier patient dans l\u2019expansion europ\u00e9enne de son essai clinique de Phase I \/ II DOMISOL \u00e9valuant DT-7012, un anticorps monoclonal propri\u00e9taire anti-CCR8 d\u00e9pl\u00e9tant les Tregs, chez des patients atteints de tumeurs solides avanc\u00e9es.<\/p>\n\n\n\n<p>Cette administration de dose fait suite au lancement de l\u2019\u00e9tude DOMISOL de&nbsp;<a href=\"https:\/\/www.kainovatx.com\/wp-content\/uploads\/default\/20260202\/kainova-pr-28102025-fr.pdf\">Phase I \/ II en Australie, annonc\u00e9 en octobre 2025<\/a>, et marque une \u00e9tape importante dans le d\u00e9veloppement clinique mondial de DT-7012, le programme phare en immuno-oncologie de Kainova Th\u00e9rapeutiques. L\u2019expansion europ\u00e9enne (&nbsp;<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06819735\">NCT06819735<\/a>&nbsp;) regroupe des centres d\u2019oncologie de r\u00e9f\u00e9rence en France, dirig\u00e9s par des investigateurs experts des phases pr\u00e9coces, notamment Dr Lauriane Eberst aux H\u00f4pitaux Universitaires de Strasbourg, Professor Antoine Italiano \u00e0 l\u2019Institut Gustave Roussy \u00e0 Paris, et Dr Maxime Brunet \u00e0 l\u2019Institut Bergoni\u00e9 \u00e0 Bordeaux.<\/p>\n\n\n\n<p><strong>Professeur Antoine Italiano, D.M. PhD, responsable du programme de m\u00e9decine de pr\u00e9cision \u00e0 Gustave Roussy et membre du conseil consultatif scientifique de Kainova Th\u00e9rapeutiques<\/strong>, a d\u00e9clar\u00e9&nbsp;:&nbsp;<em>\u201cCette \u00e9tude r\u00e9unit une expertise clinique solide et des capacit\u00e9s translationnelles avanc\u00e9es, cr\u00e9ant une opportunit\u00e9 importante d\u2019\u00e9valuer comment une d\u00e9pl\u00e9tion cibl\u00e9e pourrait se traduire par un b\u00e9n\u00e9fice pour les patients atteints de tumeurs solides avanc\u00e9es. DT-7012 propose une approche nouvelle et diff\u00e9renci\u00e9e pour cibler pr\u00e9cis\u00e9ment la biologie de CCR8 et remodeler le microenvironnement tumoral.\u201d<\/em><br><br><strong>Docteur Jean-Marie Cuillerot, D.M., chef de la direction m\u00e9dicale de Kainova Th\u00e9rapeutiques<\/strong>, a ajout\u00e9&nbsp;:&nbsp;<em>\u201cLe traitement du premier patient en Europe marque une \u00e9tape cl\u00e9 dans la maturation clinique de notre programme phare, DT-7012. L\u2019\u00e9tude DOMISOL a \u00e9t\u00e9 con\u00e7ue pour g\u00e9n\u00e9rer un profil clinique et biologique complet de DT-7012, en monoth\u00e9rapie comme en combinaison, incluant des biopsies appari\u00e9es permettant d\u2019\u00e9valuer directement la d\u00e9pl\u00e9tion des Tregs au sein de la tumeur. Ces donn\u00e9es seront essentielles pour \u00e9clairer la s\u00e9lection de dose et soutenir les prochaines phases de d\u00e9veloppement.\u201d<\/em><br><br>L\u2019\u00e9tude clinique DOMISOL de Phase I\/II est une \u00e9tude multicentrique et en ouvert qui \u00e9value DT-7012 en monoth\u00e9rapie dans une Phase I d\u2019escalade de dose, en combinaison avec l\u2019inhibiteur de point de contr\u00f4le immunitaire pembrolizumab dans une Phase Ib d\u2019escalade de dose chez des patients atteints de tumeurs solides avanc\u00e9es, ainsi que dans certains types tumoraux dans une Phase II ax\u00e9e sur l\u2019efficacit\u00e9 clinique. &nbsp;Les objectifs principaux incluent la d\u00e9termination de la dose maximale tol\u00e9r\u00e9e ( DMT ) ou de la dose maximale administr\u00e9e ( DMA ) de DT-7012 en monoth\u00e9rapie, ainsi que l\u2019\u00e9valuation du profil de tol\u00e9rance de DT-7012 en combinaison avec le pembrolizumab.<\/p>\n\n\n\n<p><strong>Sean A. MacDonald, chef de la direction de Kainova Th\u00e9rapeutiques<\/strong>, a conclu&nbsp;:&nbsp;<em>\u201cEn tant que programme phare, DT-7012 est au c\u0153ur de la strat\u00e9gie de Kainova Th\u00e9rapeutiques et refl\u00e8te notre engagement \u00e0 d\u00e9velopper des th\u00e9rapies innovantes ciblant les RCPGs en immuno-oncologie et en inflammation. Avec plusieurs jalons strat\u00e9giques majeurs en perspective, 2026 est une ann\u00e9e charni\u00e8re pour Kainova Th\u00e9rapeutiques. Nous sommes ravis d\u2019\u00e9tendre l\u2019essai DOMISOL en Europe et impatients de partager des donn\u00e9es prometteuses dans les prochains mois.\u201d<\/em><\/p>\n\n\n\n<p><strong>FIN<\/strong><\/p>\n\n\n\n<p><strong>Pour plus d\u2019information, vous pouvez contacter:<\/strong><br>Optimum Strategic Communications (Anglais)<br>Mary Clark, Zoe Bolt, Elena Bates, Nellie Stephens<br>+44 (0) 203 882 9621<br><a href=\"mailto:kainova@optimumcomms.com\">kainova@optimumcomms.com<\/a><\/p>\n\n\n\n<p>Kainova Th\u00e9rapeutiques (Fran\u00e7ais)<br><a href=\"mailto:communication@kainovatx.com\">communication@kainovatx.com<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.kainovatx.com\/fr\/press-releases\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/\">&nbsp;Lire le communiqu\u00e9 original&nbsp;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Montr\u00e9al, Canada \u2013 Strasbourg, France \u2013 Boston, \u00c9tats-Unis, 9 Avril, 2026:&nbsp;Kainova Th\u00e9rapeutiques ( \u00ab la Soci\u00e9t\u00e9 \u00bb ), un acteur cl\u00e9 dans l\u2019innovation th\u00e9rapeutique en immuno-oncologie et en inflammation, a [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1826,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[115],"class_list":["post-1827","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs | adMare\" \/>\n<meta property=\"og:description\" content=\"Montr\u00e9al, Canada \u2013 Strasbourg, France \u2013 Boston, \u00c9tats-Unis, 9 Avril, 2026:&nbsp;Kainova Th\u00e9rapeutiques ( \u00ab la Soci\u00e9t\u00e9 \u00bb ), un acteur cl\u00e9 dans l\u2019innovation th\u00e9rapeutique en immuno-oncologie et en inflammation, a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T13:07:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:07:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1198\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \\\/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs\",\"datePublished\":\"2026-04-09T13:07:30+00:00\",\"dateModified\":\"2026-06-26T13:07:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/\"},\"wordCount\":654,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/\",\"name\":\"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \\\/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"datePublished\":\"2026-04-09T13:07:30+00:00\",\"dateModified\":\"2026-06-26T13:07:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/zymeworks-en-1768231861.png\",\"width\":1198,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \\\/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs | adMare","og_description":"Montr\u00e9al, Canada \u2013 Strasbourg, France \u2013 Boston, \u00c9tats-Unis, 9 Avril, 2026:&nbsp;Kainova Th\u00e9rapeutiques ( \u00ab la Soci\u00e9t\u00e9 \u00bb ), un acteur cl\u00e9 dans l\u2019innovation th\u00e9rapeutique en immuno-oncologie et en inflammation, a [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/","og_site_name":"adMare","article_published_time":"2026-04-09T13:07:30+00:00","article_modified_time":"2026-06-26T13:07:30+00:00","og_image":[{"width":1198,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs","datePublished":"2026-04-09T13:07:30+00:00","dateModified":"2026-06-26T13:07:30+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/"},"wordCount":654,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/","name":"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","datePublished":"2026-04-09T13:07:30+00:00","dateModified":"2026-06-26T13:07:30+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/zymeworks-en-1768231861.png","width":1198,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/kainova-therapeutiques-etend-lessai-clinique-de-phase-i-ii-domisol-avec-le-traitement-du-premier-patient-en-europe-evaluant-dt-7012-un-anticorps-anti-ccr8-depletant-les-tregs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Kainova Th\u00e9rapeutiques \u00e9tend l\u2019essai clinique de Phase I \/ II DOMISOL avec le traitement du premier patient en Europe \u00e9valuant DT-7012, un anticorps anti-CCR8 d\u00e9pl\u00e9tant les Tregs"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1827","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1827"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1827\/revisions"}],"predecessor-version":[{"id":1828,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1827\/revisions\/1828"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1826"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1827"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1827"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1827"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1827"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}